首页> 美国卫生研究院文献>other >Development and Validation of a High-density Fluorescence Polarization-based Assay for the Trypanosoma RNA Triphosphatase TbCet1
【2h】

Development and Validation of a High-density Fluorescence Polarization-based Assay for the Trypanosoma RNA Triphosphatase TbCet1

机译:锥虫RNA三磷酸酶TbCet1的基于高密度荧光偏振的测定方法的开发和验证。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

RNA triphosphatases are attractive and mostly unexplored therapeutic targets for the development of broad spectrum antiprotozoal, antiviral and antifungal agents. The use of malachite green as a readout for phosphatases is well characterized and widely employed. However, the reaction depends on high quantities of inorganic phosphate to be generated, which makes this assay not easily amenable to screening in 1536-well format. The overly long reading times required also prohibit its use to screen large chemical libraries. To overcome these limitations, we sought to develop a fluorescence polarization (FP) -based assay for triphosphatases, compatible with miniaturization and fast readouts. For this purpose, we took advantage of the nucleoside triphosphatase activity of this class of enzyme to successfully adapt the Transcreener ADP assay based on the detection of generated ADP by immunocompetition fluorescence polarization to the RNA triphosphatase TbCet1 in 1536-well format. We also tested the performance of this newly developed assay in a pilot screen of 3,000 compounds and we confirmed the activity of the obtained hits. We present and discuss our findings and their importance for the discovery of novel drugs by high-throughput screening.
机译:RNA三磷酸酶是广谱抗原生动物,抗病毒和抗真菌药物开发的诱人且大多未经探索的治疗靶标。孔雀石绿作为磷酸酶的读数已得到很好的表征和广泛应用。但是,该反应取决于要生成的大量无机磷酸盐,这使得该测定方法不易接受1536孔形式的筛选。所需的过长读取时间也禁止其用于筛选大型化学文库。为了克服这些局限性,我们寻求开发一种基于荧光偏振(FP)的三磷酸酶测定方法,与小型化和快速读数兼容。为此,我们利用此类酶的核苷三磷酸酶活性,成功地基于通过免疫竞争荧光偏振法检测生成的ADP来对RNA三磷酸酶TbCet1在1536中的检测,成功地适应了Transcreener ADP分析格式。我们还在3,000种化合物的初步筛选中测试了这种新开发的测定方法的性能,并且我们确认了所获得命中的活性。我们提出并讨论我们的发现及其通过高通量筛选发现新药的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号